Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.925,80
-0,11%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Keros Therapeutics Inc (KROS) Keros Therapeutics Inc (KROS) Notizie

Keros Therapeutics Inc

KROS
60,57
3,47 (6,08%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/3/202413:00GLOBEKeros Therapeutics Announces U.S. FDA Fast Track Designation..
06/3/202414:01EDGAR2Form 8-K - Current report
05/3/202414:02EDGAR2Form 8-K - Current report
05/3/202414:01EDGAR2Form 8-K - Current report
05/3/202414:00GLOBEKeros Therapeutics to Present at Leerink Partners 2024..
28/2/202422:02EDGAR2Form 8-K - Current report
28/2/202422:01GLOBEKeros Therapeutics Reports Recent Business Highlights and..
23/2/202423:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202402:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202402:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202414:00GLOBEKeros Therapeutics To Present at Pulmonary Vascular Research..
09/1/202414:01EDGAR2Form 8-K - Current report
09/1/202414:00GLOBEKeros Therapeutics Announces Closing of Upsized Public..
08/1/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:04EDGAR2Form 8-K - Current report
04/1/202422:04EDGAR2Form 144 - Report of proposed sale of securities
04/1/202422:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/1/202403:29GLOBEKeros Therapeutics Announces Pricing of Upsized Public..
03/1/202422:05GLOBEKeros Therapeutics Announces Proposed Public Offering of..
03/1/202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/1/202414:04EDGAR2Form 8-K - Current report
11/12/202312:02EDGAR2Form 8-K - Current report
11/12/202312:00GLOBEKeros Therapeutics Presents Clinical Data from its KER-050..
07/11/202314:01EDGAR2Form 8-K - Current report
07/11/202314:00GLOBEKeros Therapeutics to Present at Upcoming Healthcare..
06/11/202314:11EDGAR2Form 8-K - Current report
06/11/202314:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202314:01EDGAR2Form 8-K - Current report
06/11/202314:00GLOBEKeros Therapeutics Reports Recent Business Highlights and..
02/11/202314:00GLOBEKeros Therapeutics to Present at the 65th American Society..
04/10/202314:01EDGAR2Form 8-K - Current report
04/10/202314:00GLOBEKeros Therapeutics Presents Preclinical Data from its..
05/9/202314:02EDGAR2Form 8-K - Current report
05/9/202314:00GLOBEKeros Therapeutics to Present at Upcoming Healthcare..
07/8/202322:02EDGAR2Form 8-K - Current report
07/8/202314:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202314:00EDGAR2Form 8-K - Current report
07/8/202314:00GLOBEKeros Therapeutics Reports Recent Business Highlights and..
27/7/202322:01GLOBECorrected: Keros Therapeutics to Host Conference Call and..
24/7/202314:01EDGAR2Form 8-K - Current report
24/7/202314:00GLOBEKeros Therapeutics to Host Conference Call and Webcast to..
12/6/202314:00GLOBEKeros Therapeutics Announces Update to Participation at the..
09/6/202312:00GLOBEKeros Therapeutics Presents Clinical Trial and Preclinical..
07/6/202314:00GLOBEKeros Therapeutics to Present at Goldman Sach’s 44th Annual..
22/5/202315:00GLOBEKeros Therapeutics Presents Preclinical and Clinical Data..
11/5/202322:01GLOBEKeros Therapeutics to Present at the 28th Annual Congress of..
Apertura: 57,32 Min: 57,32 Max: 62,19
Chiusura: 57,10

La tua Cronologia

NASDAQ
KROS
Keros Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network